DYSL : Summary for Dynasil Corporation of America - Yahoo Finance

U.S. Markets closed

Dynasil Corporation of America (DYSL)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.15-0.10 (-8.00%)
At close: 4:00 PM EST
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close1.25
Bid1.19 x 300
Ask1.40 x 200
Day's Range1.15 - 1.40
52 Week Range0.89 - 2.01
Avg. Volume27,996
Market Cap19.37M
PE Ratio (TTM)57.50
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire11 days ago

    Dynasil's RMD Subsidiary Awarded $1.9 Million in Technology Development Grants by The National Institute of Health

    NEWTON, Mass., Nov. 29, 2016 /PRNewswire/ -- Dynasil Corporation of America (DYSL) today announced that its contract research subsidiary, RMD Inc., has received three Phase I and one Phase II grants totaling $1.9 million under the National Institute of Health's SBIR funding program.

  • PR Newswire19 days ago

    Dynasil Corporation Schedules Conference Call To Discuss Next Steps for Xcede Technologies

    NEWTON, Mass., Nov. 21, 2016 /PRNewswire/ --  Dynasil Corporation of America (NASDAQ: DYSL) will hold a conference call for investors and analysts today, Monday, November 21, 2016 at 2:00 p.m. ET.  The ...

  • PR Newswire22 days ago

    Dynasil Corporation and Cook Biotech Inc. Join Together to Advance Xcede Technologies Patch through First in Human Trials

    ROCHESTER, Minn., Nov. 18, 2016 /PRNewswire/ -- Dynasil Corporation of America (DYSL) today announced that it has made a commitment for a further $1.2 million investment in subsidiary Xcede Technologies, Inc. This investment comes alongside a commitment from Cook Biotech Inc. (CBI) of West Lafayette, Ind., to manage the Xcede Patch first-in-human clinical study on behalf of Xcede in exchange for secured loan considerations of up to $1.5 million. In addition, Peter Sulick, Dynasil Chairman and CEO, and members of his family made an additional investment of $450,000.  It is anticipated this $3.15 million funding will be sufficient for Xcede to complete first-in-human clinical trials and related preclinical tests. The Xcede Patch is intended to be used during surgical procedures to stop bleeding (hemostasis).  Preclinical testing to date indicates this product promotes hemostasis within 60 seconds, a time that is faster than currently approved hemostatic patches, which take approximately three minutes to stop bleeding.